Navigation Links
Research!America Honors Univ. of Chicago Economists for Study Showing Economic Impact of HIV/AIDS Drug Development
Date:10/9/2007

WASHINGTON, Oct. 9 /PRNewswire-USNewswire/ -- Research!America today presented its 2007 Eugene Garfield Economic Impact of Medical and Health Research Award to two University of Chicago economists. Tomas Philipson, Ph.D., and Anupam Jena, Ph.D., were honored for their study "Who Benefits from New Medical Technologies?" published in Forum for Health Economics and Policy.

Using a novel approach, Philipson and Jena measure the value of HIV/AIDS drugs developed from 1980 to 2000. They calculate nearly $1.4 trillion in total value -- past and future -- to consumers from these drugs, based on the resulting gains in survival. They also estimate past and future profits for producers of the drugs to be nearly $63 billion -- or 5% of the total value. The authors conclude that such relatively low profits could reduce the incentive for producers to develop future HIV/AIDS treatments. They recommend exploring ways to raise the value to producers of new medical technologies in order to encourage further innovation.

Mark McClellan, MD, Ph.D., former Centers for Medicare and Medicaid Services administrator, and Eugene Garfield, Ph.D., the award benefactor, presented the award to Philipson and Jena today in Washington, DC. The award is named for Garfield, president and founding editor of The Scientist and creator of the Science Citation Index. McClellan headed the award selection committee. Both are Research!America board members.

Presenting the award, McClellan noted the contributions of past recipients and the need to build on their work.

"While the opportunity to understand and prevent disease and its complications has never been greater, the challenge for promoting effective, efficient use of increasingly diverse and sophisticated treatments has also never been greater," he said. "Expanding our knowledge of the economic impact of medical and health research will help overcome the challenges on the path to better health that we all know lies ahead."

Citing the importance of the Garfield Award in encouraging further study in this area, Mary Woolley, Research!America's president, said, "We need much more work like that of Dr. Philipson and Dr. Jena to show how important health-related research is for our nation's economy as well as our length and quality of life."

About the 2007 Recipients

Tomas Philipson, Ph.D., is a tenured professor in the Irving B. Harris Graduate School of Public Policy Studies at the University of Chicago. He is also a faculty member of the university's Department of Economics and its Law School. One of the nation's leading experts in the field of health economics, he has served as a senior economic adviser to the U.S. government.

Anupam Jena completed his Ph.D. in economics at the University of Chicago in 2006 as part of the University's Medical Scientist (MD/Ph.D.) Training Program. He is currently a third-year medical student at the University of Chicago and a Bing Center Visiting Fellow at the Rand Corporation. His research has focused on the economic value of medical innovation, implications of cost-effectiveness policies for technological growth and the economics of fertility.

About Research!America

Research!America is the nation's largest not-for-profit public education and advocacy alliance working to make research to improve health a higher national priority. Founded in 1989, Research!America is supported by more than 500 member organizations that represent the voices of more than 125 million Americans.

Ms. Woolley is available for further comment.


'/>"/>
SOURCE Research!America
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. US Academy honors 15 for major contributions to science
2. American Cancer Society Honors Exemplary Cancer Caregivers
3. Johns Hopkins Medicine Honors U.A.E. Sheikh Zayed Bin Sultan Al Nahyan
4. Baltimore is Americas Fittest City; Chicago the Fattest
5. Chicago :FDA imposes Ban on Biomedical Tissue Services
6. Chicago: Dad, I need you desperately, Please come back
7. Couples To Swap Kidneys In Chicago
8. Funds Allocated to Illinois and Chicago to Prepare in Case of a Flu Pandemic
9. Food Poisoning at the Chicago Food Festival
10. Rural Canadians travel far for specialists: study
11. A new study surpasses Gene Therapy Hurdle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a ... innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are used ... to accelerate tissue synthesis and provide a faster and more efficient healing process. ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... The SeniorCare ... the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording ... is part of the Interactive Webinar Series. , If you want to find out ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... suffer from combat-related PTSD. , Established in 1977, our organization was at the ... of military returning to civilian life were evident and served as the catalyst ...
(Date:2/22/2017)... Wis (PRWEB) , ... February 22, 2017 , ... ... a category by itself - the Vector™ Series Multi-Cook Oven offers up to ... oven chamber, featuring exclusive Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & ... in Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon ... clinic employees, the construction team and tribal leadership. , Choctaw Nation Durant ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Research and Markets has announced the addition of ... Infrared, Mercury; Trend Indicator):Analysis By Region, By Country (2016-21)" report ... ... at a CAGR of 5.33% during 2016-2021 The strong ... with surging demand of digital thermometer. Apart from that, the downfall ...
(Date:2/22/2017)... 2017 Oncternal Therapeutics, Inc., a clinical-stage ... and common malignancies, today announced the closing of ... intends to use the proceeds to further clinical ... advance preclinical development of a new ROR1-targeted antibody-drug ... first-in-class anti-ROR1 monoclonal antibody being developed to treat ...
(Date:2/22/2017)... 22, 2017 Kineta, Inc., a biotechnology ... immune modulating therapies, today announced that KCP-400 (RgIA4), ... receptor (nAChR), demonstrates robust chronic pain relief and ... study also establishes the a9a10 nAChR as a ... pain. The findings were reported online in the ...
Breaking Medicine Technology: